VivoSeq
Respiratory

Chronic Rhinosinusitis

70

Pipeline Programs↗

17

Active Trials↗

31

Companies Involved↗

Chronic Rhinosinusitis is a moderately active landscape with 70 programs across 31 companies. The most active players are Vertex Pharmaceuticals, Hikma Pharmaceuticals LLC, Viatris Specialty LLC. 14 therapies are approved with 21 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

65/100

Pipeline Velocity

15/100

Mech. Concentration

21/100

Completion Rate

82/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

1 program

Phase 1H

Hikma Pharmaceuticals LLC

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 2Eli Lilly logo

Eli Lilly

3 programs

Phase 3GSK logo

GSK

1 program

Phase 3Amgen logo

Amgen

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical16

Mepolizumab

Glaxo Dba Glaxosmithkline

Ergocalciferol

Alnylam Pharmaceuticals

Erythromycin

Azurity Pharmaceuticals

Lidocaine

MEDRx USA, Inc.

Tranexamic Acid

Amring

Phase 16

Triamcinolone

Bassett Healthcare

Ivacaftor

Vertex Pharmaceuticals

Omalizumab

Roche

Mupirocin

Padagis LLC

Povidone-Iodine

Becton, Dickinson and Company

Phase 213

CM326

Keymed Biosciences Co.Ltd

Nitric Oxide

Mallinckrodt

Benralizumab

AstraZeneca

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Simvastatin

Organon and Co

Phase 321

Rimegepant

Pfizer

Fluticasone Propionate

GSK

Ibuprofen

Kenvue Brands

Reslizumab

Teva

Dornase Alfa

Roche

Approved14

Methylprednisolone

Pfizer

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Budesonide

Salix

Epinephrine

Samson Clinical Operations Pty Ltd

Analysis

Modality Breakdown

90%

Small molecule

79 of 88 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody67%Protein / enzyme22%Peptide11%

Small molecule leads; the ring shows all 88 classified programs, each share of the total. Modality classified for 100% of 92 pipeline programs.

Analysis

Trial Status

92

clinical trials

Completed49 · 53%
Unknown status15 · 16%
Not yet recruiting8 · 9%
Withdrawn7 · 8%
Recruiting7 · 8%
Terminated4 · 4%
Other2 · 2%

Clinical Trials

Trial Activity

92 trials

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment
Recruiting·SSt. Paul's Sinus Centre·Phase 4·NCT05642806·90 enrolled
Effect of Chinese Herbal Medicine Nasal Irrigation on the Postoperative Care of Chronic Rhinosinusitis
Recruiting·TTaichung Veterans General Hospital·Phase 2·NCT07340411·80 enrolled
The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients with Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery (FESS)
Recruiting·OOticara Australia PTY LTD·Phase 2·NCT05882903·24 enrolled
Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Recruiting·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT06683261·300 enrolled
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
Recruiting·MMontefiore Medical Center·N/A·NCT05246267·60 enrolled
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis
Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT03439865·20 enrolled
Steroid-eluting Sinus Stent for Chronic Rhinosinusitis Patients With Uncontrolled Postoperative Symptoms
Recruiting·—·N/A·NCT06198894·96 enrolled
The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype
Active, not recruiting·TTampere University Hospital·N/A·NCT04171167·88 enrolled
Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
Active, not recruiting·Sanofi logoSanofi·N/A·NCT06393946·150 enrolled
Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis
Not yet recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT06372678·90 enrolled
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）
Not yet recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT06930612·120 enrolled
Biologics in Chronic Rhinosinusitis With Nasal Polyposis
Not yet recruiting·MMedical University of South Carolina·Phase 4·NCT06824649·504 enrolled
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis
Not yet recruiting·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 3·NCT07420257·212 enrolled
Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps
Not yet recruiting·—·Phase 4·NCT06556264·60 enrolled
Intra-Sinus Povidone-Iodine and Budesonide After Endoscopic Sinus Surgery for Chronic Rhinosinusitis
Not yet recruiting·—·Phase 3·NCT07383402·180 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)